Loading clinical trials...
Loading clinical trials...
A Phase 2 Open-Label Study in Infants With REspiratory Syncytial VIRus Lower RespirAtory Tract Infection, Followed by a DoubLe-blind, Placebocontrolled Part, to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Effect of RV521 (REVIRAL 1)
Conditions
Interventions
RV521
Placebo
Locations
60
Argentina
Hospital Interzonal General de Agudos "Dr. José Penna"
Bahía Blanca, Buenos Aires, Argentina
Hospital Italiano Regional Del Sur
Bahía Blanca, Buenos Aires, Argentina
Hospital General de Ninos Pedro de Elizalde
Buenos Aires, Buenos Aires F.D., Argentina
Hospital de ninos "Ricardo Gutierrez"
Calgary, Alberta, Canada
Hospital Base San Jose Osorno
Osorno, Los Lagos Region, Chile
Hospital de Ninos Dr. Roberto del Rio
Santiago, Santiago Metropolitan, Chile
Start Date
November 13, 2019
Primary Completion Date
December 5, 2022
Completion Date
December 5, 2022
Last Updated
October 23, 2024
NCT05045612
NCT06998251
NCT06521944
NCT07249320
NCT07128121
NCT04896853
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions